This is in accordance with our finding that patients with ER-/PR- tumor subtypes displayed a significantly higher risk of death (HR 4.74; [90% CI: 1.88-11.95]) versus IBC patients with ER+/PR+ tumor receptor subtypes. Here, PGR is linked to neoplasm.